VEGFA and cancer: There is a discrepancy between the results of retrospective population-based data such as the SEER cancer registry outcomes data and the IMDC registry data in which OS is significantly better with CN, and those seen in prospective randomized trial results such as the CARMENA and SURTIME studies that show that CN is unlikely to make an impact on improving outcomes in the setting of contemporary anti-VEGF therapy such as sunitinib (9).